Results 191 to 200 of about 2,703,409 (308)

Standardizing pCR/MPR Assessment in NSCLC After Neoadjuvant Therapy: Challenges and Perspectives. [PDF]

Cancers (Basel)
Ascione A, Adotti F, Vittori L, Chiappetta C, Graziano P.   +4 more
europepmc   +1 more source

Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Spread: A Systematic Review

Head &Neck, EarlyView.
ABSTRACT Background Immunotherapy is increasingly used for head and neck cutaneous squamous cell carcinoma (cSCC) with perineural spread (PNS), though outcomes remain poorly defined. Methods A systematic review was conducted according to PRISMA and MOOSE guidelines.
Jai Paris, James Tsimiklis, Ayushi Agarwal, Jessica Y. Tong, Dinesh Selva   +4 more
wiley   +1 more source

Leveraging endocrine sensitivity in ER-positive DCIS: Neoadjuvant therapy and nonoperative management. [PDF]

Breast
Semba R, Childs S, Saw K, Segara D, Mann GB, Shien T, Birrell S, Horimoto Y, Kutomi G, Lim E.   +9 more
europepmc   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia, Anne‐Sophie van der Werf‐'t Lam, Madalina Cabuta, Maartje Nielsen, Noah C. Helderman   +4 more
wiley   +1 more source

Identification of Factors That Determine Adherence for Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer. [PDF]

Cancers (Basel)
Araradian C, Hunnicutt E, Chen S, Rivedal S, Willis S, Walsh M, Tsikitis VL, Fang SH.   +7 more
europepmc   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. [PDF]

Langenbecks Arch Surg
Halimi A, Zwart ES, Yilmaz BS, Kurlinkus B, Ahola R, Del Chiaro M, Sparrelid E, Rangelova E, Maggino L, Malleo G, Lionetto G, Salvia R, Roberts KJ, Giovinazzo F, Falconi M, Crippa S, Belfiori G, Kazemier G, Maisonneuve P, Laukkarinen J, Ceyhan GO.   +20 more
europepmc   +1 more source

Perioperative Rehabilitation and Initiation of Adjuvant Chemotherapy in Resected Non‐Small Cell Lung Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant chemotherapy can improve outcomes for patients who have undergone lung cancer resection, and perioperative rehabilitation may help maintain the physical condition necessary to receive adjuvant chemotherapy. This observational cohort study investigated the impact of perioperative rehabilitation on the administration of postoperative ...
Shinkichi Takamori, Tateaki Naito, Nobuko Konishi, Tetsuya Tsuji, Ikumi Takashima, Ryotaro Ide, Masakazu Fujiwara, Atsuki Yamamoto, Yusuke Takagi, Mizue Ogi, Shinya Uematsu, Hiroshi Kitagawa, Koichi Takayama   +12 more
wiley   +1 more source

The Landmark Series: Neoadjuvant Therapy for Patients with Resectable Gastroesophageal Junction Adenocarcinomas. [PDF]

Ann Surg Oncol
Pettigrew MF, Coburn NG, Woo Y, Porembka MR.   +3 more
europepmc   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source